Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular, and metabolic diseases; consumer products in oral care, baby care, beauty, over the counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, neurovascular care, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.
Headquarters
United States of America
Address
One Johnson & Johnson Plaza, New Brunswick, New Jersey, 08933
Website
www.jnj.com
Telephone
1 732 5242455
No of Employees
152,700
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
JNJ (NYSE)
Revenue (2022)
$94.9B
1.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-14.1%
(2022 vs 2021)
Market Cap*
$389.3B
Net Profit Margin (2022)
XYZ
-15.1%
(2022 vs 2021)
* As of and is in US$
Johnson & Johnson premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pharmaceutical | Johnson’s |
| Immunology: | Listerine |
| Rheumatoid Arthritis | Aveeno |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In September, The Janssen Pharmaceutical Cos changed its name to Johnson & Johnson Innovative Medicine. |
| 2023 | Corporate Changes/Expansions | In September, the company rebranded with a new logo. |
| 2023 | Others | In September, the company's Janssen Pharmaceutical Companies filed a marketing authorisation application with the European Medicines Agency for erdafitinib to treat locally advanced unresectable or metastatic urothelial carcinoma. |
Competitor Comparison
| Key Parameters | Johnson & Johnson | Pfizer Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | Switzerland |
| City | New Brunswick | New York | Basel | Kenilworth | Basel |
| State/Province | New Jersey | New York | - | New Jersey | - |
| No. of Employees | 152,700 | 83,000 | 103,613 | 69,000 | 103,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joaquin Duato | Chairman; Chief Executive Officer | Executive Board | 2023 | 60 |
| Joseph J. Wolk | Chief Financial Officer; Executive Vice President | Senior Management | 2018 | 56 |
| James Swanson | Executive Vice President; Chief Information Officer | Senior Management | 2022 | 57 |
| William N. Hait, M.D., Ph. D. | Interim Head- Janssen R&D; Chief External Innovation and Medical Safety Officer; Executive Vice President | Senior Management | 2022 | 73 |
| Peter M. Fasolo, Ph.D. | Executive Vice President; Chief Human Resources Officer | Senior Management | 2016 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward